Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘plos one’ Category

Caught Our Notice: Another retraction for researcher paid $100k to leave uni

without comments

Via Wikimedia

When Retraction Watch began in 2010, our co-founders Ivan Oransky and Adam Marcus quickly realized they couldn’t keep up with the hundreds of retractions that appeared each year.  And the problem has only gotten worse — although we’ve added staff, the number of retractions issued each year has increased dramatically. According to our growing database, just shy of 1,000 retractions were issued last year (and that doesn’t include expressions of concern and errata). So to get new notices in front of readers more quickly, we’ve started a new feature called “Caught our Notice,” where we highlight a recent notice that stood out from the others. If you have any information about what happened, feel free to contact us at retractionwatchteam@gmail.com.

Title:  Diabetes and Overexpression of proNGF Cause Retinal Neurodegeneration via Activation of RhoA Pathway  and  Diabetes-Induced Superoxide Anion and Breakdown of the Blood-Retinal Barrier: Role of the VEGF/uPAR Pathway 

What caught our attention:

Read the rest of this entry »

Case closed? Fired Pfizer researcher slated for seven retractions

without comments

Pfizer has discovered two additional papers that merit retraction from the lab of a former employee. One of the papers, published in Clinical Cancer Research, was retracted earlier this month.

Last year, Pfizer requested retractions of five papers from the lab of breast cancer researcher Min-Jean Yin, who was fired after an investigation revealed image duplication. The papers were first questioned on PubPeer. By April 2017, all five papers had been retracted.

After the initial probe, the pharmaceutical giant conducted a follow-up review of papers originating from Yin’s lab (which Leonid Schneider posted about on May 23). A spokesperson for the company told us that the review revealed two more articles that merited retraction “in light of data integrity issues relating to the figures therein.” The 2013 paper in Clinical Cancer Research was retracted earlier this month at Pfizer’s request. On May 1, 2017, Pfizer asked PLOS ONE to retract 2013 paper. Read the rest of this entry »

Written by Victoria Stern

August 28th, 2017 at 8:13 am

PLOS ONE retracts paper after researcher admits to fabricating data

with 2 comments

On June 19, 2017, the U.S. Office of Research Integrity published its first misconduct finding of the year. The ORI reported that Brandi M. Baughman — a former research training awardee at the National Institute of Environmental and Health Sciences (NIEHS) — had “falsified and/or fabricated data” in 11 figures in a 2016 paper published in PLOS ONE.

Two days later, on June 21, PLOS ONE retracted the paper. (Note: The retraction process proceeded relatively quickly, but took longer than two days; a spokesperson for the journal told us that the authors alerted the editors of their concerns about the publication in May.)   Read the rest of this entry »

Written by Victoria Stern

July 26th, 2017 at 8:00 am

NIH researcher doctored 11 figures in 2016 paper, says ORI

with 3 comments

A former Research Training Awardee at the National Institutes of Health “falsified and/or fabricated data” in 11 figures in a 2016 paper, according to the U.S. Office of Research Integrity.

This is the first finding of misconduct issued this year by the ORI.

According to the finding, published in the Federal Register, Brandi M. Baughman — formerly at the National Institute of Environmental and Health Sciences (NIEHS) — tweaked data and text in a PLOS ONE paper about screening for compounds that inhibit an enzyme known as inositol phosphate kinase. According to the notice, however, some of those experiments didn’t proceed as described:

Read the rest of this entry »

Written by Alison McCook

June 19th, 2017 at 3:09 pm

PLOS upgrades flag on controversial PACE chronic fatigue syndrome trial; authors “surprised”

with 9 comments

PLOS ONE has issued an expression of concern after the authors of a controversial study about chronic fatigue syndrome declined to share some of their data.

In an unusual move, the journal included the authors’ response to the expression of concern (EOC), in which they strongly argue against the notice, and “do not accept that it is justified.”

In 2015, following public requests to review the data, the journal issued an “editor’s note” on the paper, noting the journal’s policy that authors make data and materials available.

There have been numerous requests for data from the “PACE” trial, as the clinical trial is known. Patients and advocates have long disputed the results, arguing that suggesting cognitive behavior and graded exercise therapy could cause harm.

In the latest notice, the journal says it consulted two editorial board members about the paper, a 2012 sub analysis of a controversial clinical trial on chronic fatigue syndrome. The journal then asked the authors to provide the data behind five tables, which would enable researchers to replicate the cost-effectiveness analyses the authors report for different therapies — including graded exercise therapy, which some patient advocates believe could be harmful.

As with previous requests for data, the authors refused to provide it, citing patient confidentiality and consent. The notice explains:

Read the rest of this entry »

Written by Alison McCook

May 2nd, 2017 at 2:54 pm

Fired Pfizer cancer researcher loses final two of five papers pegged for retraction

without comments

PLOS ONE has retracted the last of five papers by a former employee of Pfizer, who the company fired after determining she had duplicated data.

After its investigation, Pfizer asked journals to retract five papers co-authored by Min-Jean Yin. Last week, PLOS ONE retracted the final two remaining papers. Both notices cite image duplications; Yin contacted the journal about one paper, but did not comment on the other retraction.

Here’s the notice for “miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells:”

Read the rest of this entry »

How many scientists admit to questionable research practices?

with 3 comments

Franca Agnoli

Sure, everyone knows it’s not a good idea to falsify data. But what about somewhat lesser offenses that also undermine the reproducibility of your findings, such as only publishing studies that “work,” and reporting an unexpected finding as something you had predicted from the beginning? In 2012, a survey of more than 2,000 psychologists based in the U.S. found that most admitted to adopting at least one “questionable research practice.” But would psychologists in other countries say the same? (Answer: Yes.) A group of researchers led by Franca Agnoli at the University of Padova posed this question to 277 Italian psychologists; their results appear in PLOS ONE

Retraction Watch: Why is it important to compare how many researchers engage in questionable practices in different countries? 

Read the rest of this entry »

Written by Alison McCook

March 31st, 2017 at 9:30 am

Author duplicated a figure in three papers; two get retracted

without comments

Two journals have retracted two papers by the same group within months of each other, after editors were independently tipped off that they contained duplicated figures representing different experiments.

The two papers were published by PLOS ONE and The Egyptian Journal of Biochemistry and Molecular Biology (EJBMB) in 2015 and 2014, respectively. According to the PLOS ONE paper’s corresponding author, last author Saad A. Noeman from Tanta University in Egypt used the same Figure 1 in both papers, along with another 2013 paper in EJBMB.

Corresponding author Yasser S. El-Sayed, head of the Department of Forensic Medicine and Toxicology at Damanhour University in Egypt, told us he learned of this issue after a reader brought the figure manipulation and duplication concerns to PLOS ONE’s attention.

El-Sayed said that he tried to figure out what had happened.

Read the rest of this entry »

PLOS ONE has faced a decline in submissions – why? New editor speaks

with 11 comments

By some measures, 2016 was a somewhat rocky year for PLOS ONE — it issued some high-profile retractions, and published fewer papers, in part due to a decline in submissions. Still, the first multidisciplinary open-access journal — which accepts all submissions that meet technical and ethical standards, regardless of the results — publishes more than 20,000 papers per year, juggling thousands of editors and reviewers. So what does the future hold for this “large and complex” journal? We spoke with its new editor, Joerg Heber, who assumed the role in November.

Retraction Watch: What are your primary goals for the journal, and how do you plan to achieve them?

Read the rest of this entry »

Written by Alison McCook

March 15th, 2017 at 9:42 am

Posted in plos,plos one

Authors in Spain issue string of corrections

with 2 comments

Following a journal probe and questions on PubPeer about their work, authors in Spain have issued four corrections, citing missing raw data for experiments conducted more than 10 years ago.

All papers include the same last two authors, Mireia Duñach at the Autonomous University of Barcelona, and Antonio García de Herreros at the Institut Hospital del Mar d’Investigacions Mèdiques.

Three of the corrections were issued by the Journal of Biological Chemistry, from which the authors retracted three papers earlier this year after a journal investigation concluded they contain reused images, designed to represent different experiments.

Duñach told us the latest corrections are the result of her own initiation:

Read the rest of this entry »

Written by Alison McCook

December 30th, 2016 at 9:30 am